What is Zacks Research’s Forecast for AXSM FY2024 Earnings?

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Analysts at Zacks Research decreased their FY2024 earnings per share estimates for shares of Axsome Therapeutics in a research report issued on Tuesday, January 7th. Zacks Research analyst R. Department now anticipates that the company will post earnings per share of ($5.42) for the year, down from their previous forecast of ($5.32). The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($4.60) per share. Zacks Research also issued estimates for Axsome Therapeutics’ Q4 2024 earnings at ($1.75) EPS, Q1 2025 earnings at ($1.71) EPS, Q2 2025 earnings at ($1.60) EPS, Q3 2025 earnings at ($1.16) EPS, Q4 2025 earnings at ($1.29) EPS, FY2025 earnings at ($5.77) EPS, Q1 2026 earnings at ($0.61) EPS, Q2 2026 earnings at ($0.23) EPS, Q3 2026 earnings at $0.11 EPS, Q4 2026 earnings at $0.06 EPS and FY2026 earnings at ($0.67) EPS.

Axsome Therapeutics (NASDAQ:AXSM) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.38) by $0.04. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. The firm had revenue of $104.76 million for the quarter, compared to analyst estimates of $98.71 million. During the same quarter in the previous year, the business posted ($1.32) earnings per share.

Other equities research analysts have also recently issued reports about the stock. Needham & Company LLC reiterated a “buy” rating and issued a $133.00 price objective on shares of Axsome Therapeutics in a report on Monday. Cantor Fitzgerald reissued an “overweight” rating and issued a $121.00 price objective on shares of Axsome Therapeutics in a research note on Thursday, December 12th. Mizuho reduced their target price on Axsome Therapeutics from $124.00 to $122.00 and set an “outperform” rating for the company in a report on Tuesday, December 31st. Robert W. Baird increased their price target on Axsome Therapeutics from $112.00 to $116.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. Finally, HC Wainwright restated a “buy” rating on shares of Axsome Therapeutics in a research note on Tuesday, December 31st. One investment analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, Axsome Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $127.29.

Axsome Therapeutics Trading Down 1.4 %

Axsome Therapeutics stock opened at $82.57 on Thursday. The company has a 50 day moving average price of $92.62 and a 200 day moving average price of $89.09. The company has a debt-to-equity ratio of 1.97, a quick ratio of 2.37 and a current ratio of 2.44. Axsome Therapeutics has a 52 week low of $64.11 and a 52 week high of $105.00. The firm has a market capitalization of $4.00 billion, a price-to-earnings ratio of -12.64 and a beta of 1.04.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in AXSM. FMR LLC raised its holdings in shares of Axsome Therapeutics by 20.6% in the 3rd quarter. FMR LLC now owns 1,088,087 shares of the company’s stock worth $97,786,000 after buying an additional 185,951 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Axsome Therapeutics by 2.7% in the 3rd quarter. Geode Capital Management LLC now owns 908,459 shares of the company’s stock valued at $81,659,000 after purchasing an additional 23,564 shares in the last quarter. Wellington Management Group LLP grew its holdings in shares of Axsome Therapeutics by 1.1% in the 3rd quarter. Wellington Management Group LLP now owns 742,745 shares of the company’s stock worth $66,750,000 after purchasing an additional 8,125 shares during the last quarter. Millennium Management LLC increased its position in shares of Axsome Therapeutics by 1.4% during the 2nd quarter. Millennium Management LLC now owns 739,819 shares of the company’s stock worth $59,555,000 after purchasing an additional 10,401 shares in the last quarter. Finally, Hood River Capital Management LLC lifted its holdings in Axsome Therapeutics by 5.4% during the 2nd quarter. Hood River Capital Management LLC now owns 549,066 shares of the company’s stock valued at $44,200,000 after purchasing an additional 28,316 shares during the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.